Home › ALLY Trial Demonstrates High Cure Rates for Investigational...
 

Keywords :   


ALLY Trial Demonstrates High Cure Rates for Investigational...

2014-11-08 23:40:51| Biotech - Topix.net

Bristol-Myers Squibb Company today announced late-breaking data from the landmark ALLY Trial investigating a ribavirin-free 12-week regimen of daclatasvir in combination with sofosbuvir in genotype 3 hepatitis C patients, a patient population that has emerged as one of the most difficult to treat. The results of the study, which showed sustained virologic response 12 weeks after treatment in 90% of treatment-nai 1 2ve and 86% of treatment-experienced patients, will be presented at The Liver Meeting 2014, the Annual Meeting of The American Association for the Study of Liver Diseases , in Boston, MA, November 7 - 11. "Both treatment nai 1 2ve and treatment experienced patients in the ALLY-3 study achieved high SVR rates.

Tags: high rates trial cure

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Atlantic Tropical Weather Outlook
29.09Eastern North Pacific Tropical Weather Outlook
29.09Hurricane Isaac Graphics
29.09Tropical Storm Joyce Graphics
29.09Hurricane Isaac Forecast Discussion Number 14
29.09Tropical Storm Joyce Forecast Discussion Number 8
29.09Hurricane Isaac Public Advisory Number 14
29.09Summary for Hurricane Isaac (AT5/AL102024)
More »